Neuronetics Achieves Strong Financial Performance
Neuronetics, Inc., a leader in medical technology focused on transforming mental health treatment, reported impressive financial and operating results. In a recent quarter, the company delivered a total revenue of $38.1 million, showcasing an 18% increase in adjusted pro forma revenue. This remarkable growth is indicative of Neuronetics' strategic operations and dedication to enhancing patient care.
Financial Highlights for the Quarter
Key highlights from this quarter demonstrate not only increased revenue but also advances in operational efficiencies. Record revenue from Greenbrook clinics reached $23.0 million for the quarter, contributing significantly to the company’s overall revenue. Additionally, Neuronetics has optimized its cash usage, lowering operational cash consumption to $3.5 million, which exceeded management's expectations of maintaining it below $5 million.
Challenging Market Conditions and Resilience
The journey was not without challenges, but Neuronetics has shown resilience. The company generated U.S. treatment session revenue of $10.8 million, marking a 13% increase on a pro forma basis compared to the same quarter in the previous year. The U.S. NeuroStar Advanced Therapy System revenue, although slightly decreased at $3.5 million, continues to indicate robust demand for innovative mental health solutions.
Operational Milestones
During the quarter, Neuronetics achieved an important milestone by treating over 209,000 global patients through its diverse treatment offerings. This success reflects the company's efforts and dedication to providing accessible mental health treatments. Furthermore, the company secured an additional $10 million in funding from Perceptive Advisors LLC under its existing debt agreement, which has broadened its financial flexibility and support for future operations.
Leadership Enhancements
The appointment of Steven Pfanstiel as Chief Financial Officer on July 15, 2025, adds significant expertise to Neuronetics' leadership. With over 20 years in healthcare experience, Pfanstiel's leadership is expected to bolster the company's strategic priorities and growth trajectory moving forward.
Looking Ahead: Business Outlook for 2025
Looking forward, the company projects total worldwide revenue between $149 million and $155 million for the full year of 2025, underpinned by a positive operational outlook. Neuronetics anticipates improvements in gross margins, estimating between 48% and 50%, primarily due to the mix of revenues from Greenbrook clinics.
For the third quarter of 2025, total worldwide revenue is forecasted to fall between $37 million and $39 million, contributing to the overall growth narrative. The company is well-positioned to turn negative cash flow into positive results by the end of 2025, reinforcing its commitment to generating sustainable growth in an increasingly competitive landscape.
Frequently Asked Questions
What were Neuronetics' total revenues for the quarter?
The company reported total revenues of $38.1 million, reflecting a strong revenue growth of 18% on an adjusted pro forma basis.
How has the Greenbrook acquisition impacted Neuronetics?
The acquisition significantly boosted the U.S. clinic revenue to $23 million and is a cornerstone of Neuronetics' successful operational strategy.
What is the company’s outlook for 2025?
Neuronetics anticipates total worldwide revenue between $149 million and $155 million, signaling robust growth plans.
Who has been appointed as the new CFO?
Steven Pfanstiel has joined Neuronetics as Chief Financial Officer, bringing invaluable healthcare experience to the leadership team.
What are the company's expectations on achieving cash flow breakeven?
Neuronetics expects to achieve positive cash flow from operations in the fourth quarter of 2025, showing solid financial resilience and strategic positioning.
